Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of its Hantavirus Research Reagents and Products to support hantavirus research and diagnostic assay development. This comprehensive catalog aims to help academic researchers, biopharmaceutical companies, and industrial organizations accelerate the development of diagnostic assays and therapeutic interventions targeting dangerous rodent-borne orthohantaviruses.
Hantaviruses are emerging zoonotic pathogens belonging to the Bunyaviridae family, classified as Category A pathogens by the US Centers for Disease Control and Prevention (CDC). These viruses pose a serious threat to human health, as infection can lead to haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS), both of which are highly fatal. Transmission occurs via aerosols containing excreta from infected rodent hosts.
The viruses possess a tripartite negative-strand RNA genome, with three genomic RNA segments (S, M and L) encoding the nucleocapsid protein (N), a precursor glycoprotein (forming envelope glycoproteins Gn and Gc), and the viral RNA-dependent RNA polymerase (RdRp). The N protein is the primary structural component, protecting and encapsidating the genomic RNA strands. Recent studies suggest the N protein acts with RdRp in transcription and replication, and preferentially promotes viral mRNA translation within cells.
Currently, no antiviral therapies or vaccines are available for hantavirus-associated diseases. A deeper understanding of the molecular mechanisms underlying the hantavirus life cycle could identify targets for antiviral therapy and aid in designing drugs to treat HFRS and HCPS. Given the alarming case-fatality rate, developing an effective hantavirus vaccine is imperative.
Early clinical manifestations of hantavirus infection often resemble common seasonal respiratory or influenza-like illnesses, necessitating highly sensitive, reliable and standardized laboratory diagnostic tools for early differential diagnosis and accurate target validation. To address these challenges, Creative Diagnostics offers a range of hantavirus research reagents and products covering multiple strains, including Hantavirus, Puumala virus (PUUV), Seoul virus (SEOV) and Sin Nombre virus (SNV).
The new product line includes: 1) Recombinant hantavirus antigens for assay development; 2) high-affinity monoclonal and polyclonal antibodies validated for capture and detection across multiple platforms, including Western blot, flow cytometry, immunohistochemistry and surface plasmon resonance; 3) supporting reagents for ELISA and rapid immunoassay research.
For detailed product specifications, volume pricing, or to browse the complete list of available viral solutions, visit the official product portal at https://www.creative-diagnostics.com/hantavirus.htm.
